Valuation: Gilead Sciences, Inc.

Market Cap 17TCr 2,95800Cr 15TCr 14TCr 13TCr 24TCr 16,09600Cr 24TCr 1,62900Cr 64TCr 7,90400Cr 63TCr 62TCr 27,37900Cr P/E 2026 *
-48.1x
P/E 2027 * 17.6x
Enterprise Value 18TCr 3,12400Cr 16TCr 14TCr 13TCr 25TCr 16,99900Cr 26TCr 1,72100Cr 67TCr 8,34800Cr 67TCr 65TCr 28,91500Cr EV / Sales 2026 *
5.84x
EV / Sales 2027 * 5.21x
Free-Float
99.88%
Yield 2026 *
2.39%
Yield 2027 * 2.48%
1 day+0.63%
Current month+0.63%
1 month-2.00%
3 months-12.26%
6 months-0.29%
Current year-0.21%
1 month 2,116
Extreme 2116
2,217.67
Current year 2,116
Extreme 2116
2,618.71
1 year 2,025.32
Extreme 2025.32
2,618.71
3 years 1,046.71
Extreme 1046.71
2,618.71
5 years 1,046.71
Extreme 1046.71
2,618.71
10 years 1,046.71
Extreme 1046.71
2,618.71
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%0.00% - - 17TCr
+0.09%+0.25%+54.65%+168.55% 1,08400Cr
-1.63%-1.50%+65.79%+62.43% 63TCr
-1.12%-4.27%+31.10%+85.82% 45TCr
+0.18%+2.04%+30.19%+26.51% 33TCr
-6.22%-3.61%+29.15%+32.09% 30TCr
-1.27%-0.56%+27.21%+46.39% 28TCr
-0.93%-1.19%-28.85%-40.38% 22TCr
-1.19%-2.81%+22.63%+61.80% 20TCr
+0.83%-0.29%-5.13%-32.03% 14TCr
Average -1.06%+1.73%+25.19%+45.69% 40.31TCr
Weighted average by Cap. -0.98%+2.16%+38.22%+80.24%

Financials

2026 *2027 *
Net sales 3.05TCr 53TCr 2.67TCr 2.46TCr 2.27TCr 4.32TCr 2,90800Cr 4.39TCr 29TCr 12TCr 1,42800Cr 11TCr 11TCr 4,94700Cr 3.24TCr 57TCr 2.83TCr 2.61TCr 2.42TCr 4.59TCr 3,09000Cr 4.66TCr 31TCr 12TCr 1,51800Cr 12TCr 12TCr 5,25700Cr
Net income -337.28Cr -5.92TCr -295.05Cr -272.09Cr -251.75Cr -477.83Cr -32TCr -485.82Cr -3.26TCr -1.28TCr -16TCr -1.27TCr -1.24TCr -55TCr 954.83Cr 17TCr 835.29Cr 770.27Cr 712.7Cr 1.35TCr 91TCr 1.38TCr 9.22TCr 3.62TCr 45TCr 3.58TCr 3.51TCr 1,55000Cr
Net Debt 946.02Cr 17TCr 827.58Cr 763.16Cr 706.12Cr 1.34TCr 90TCr 1.36TCr 9.14TCr 3.58TCr 44TCr 3.55TCr 3.47TCr 1,53600Cr -9.64Cr -169.14Cr -8.44Cr -7.78Cr -7.2Cr -14Cr -920.46Cr -14Cr -93Cr -37Cr -452.01Cr -36Cr -35Cr -1.57TCr
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
135.82USD
Average target price
158.30USD
Spread / Average Target
+16.55%

Quarterly revenue - Rate of surprise